UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2016

COHERUS BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-36721**	**27-3615821**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification Number)**

333 Twin Dolphin Drive, Suite 600
Redwood City, CA 94065
(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (650) 649-3530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Investor Presentation

On May 11, 2016, Coherus BioSciences, Inc. (the "Company") prepared an investor presentation containing certain operational information and developmental plans. Representatives of the Company intend to present some or all of this information to current investors and analysts at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada on May 11, 2016. The copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

The information disclosed under this Item 7.01 shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 shall not be deemed incorporated by reference into any filing under the Exchange Act or the United States Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Coherus BioSciences, Inc. Presentation for 2016 Bank of America Merrill Lynch Health Care Conference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 11, 2016

COHERUS BIOSCIENCES, INC.

By: /s/ Jean-Frédéric Viret
Name: Jean-Frédéric Viret
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Coherus BioSciences, Inc. Presentation for 2016 Bank of America Merrill Lynch Health Care Conference.

Exhibit 99.1

Coherus BioSciences

Bank of America Merrill Lynch Health Care Conference
May 2016

Copyright ©2016 All Rights Reserved.

Forward looking statements

Except for the historical information contained herein, the matters set forth in this presentation, including statements regarding Coherus' plans, potential opportunities, expectations, projections, goals, objectives, milestones, strategies, product pipeline, clinical studies, product development, release of data and the potential benefits of its products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including Coherus' expectations regarding its ability to advance its CHS-1701, CHS-0214,CHS-1420, CHS-5217 and CHS-3351 biosimilar drug candidates, complete bridging studies for CHS-0214 and CHS-1420, complete its follow-on PK/PD study for CHS-1701, file BLAs for CHS-1701 and CHS-1420 in the U.S., file an MAA for CHS-0214 in the E.U., file at least one IND on a second wave biosimilar pipeline candidate and enter into collaborations for CHS-1701 commercialization ex-U.S. and for its immunology (Anti-TNF) pipeline. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of our regulatory filings and other matters that could affect the availability or commercial potential of our biosimilar drug candidates. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus' business in general, see Coherus' Quarterly Report on Form 10-Q for the period ended March 31, 2016 and its future periodic reports to be filed with the Securities and Exchange Commission.

Copyright ©2016 All Rights Reserved.

Agenda

- **Introduction and Company Summary**
- Addressing the Regulatory Hurdles
- Navigating the Legal Landscape
- Maximizing the Commercial Opportunity

Copyright ©2016 All Rights Reserved.

Coherus BioSciences
is a leading pure play biosimilars company

Team

Name	Prior experience
Denny Lanfear President and CEO	AMGEN, Baxter
Jean Viret, Ph.D. Chief Financial Officer	Tularik, Corgentech, Anesiva
Alan Herman, Ph.D. Chief Scientific Officer	Genentech, AMGEN, MERCK
Barbara Finck, M.D. Chief Medical Officer	immunex, PDL BioPharma
Peter Watler, Ph.D. Chief Technical Officer	AMGEN, VaxGen, Hyde
Michael Fleming SVP, Com. Strategy	Genentech, GlaxoSmithKline, élan
Aaron Schuchart SVP, Bus. Dev.	AMGEN, NOVARTIS

Platform

- Cutting Edge Analytics
- Process Science and Molecular Tuning
- Clinical and Regulatory
- Intellectual Property

Results

- ✓ 3 products in Phase 3 or BLA-enabling trials
- ✓ 3 BLA/MAA filings targeted in 2016
- ✓ Expect to submit 1 to 2 new INDs per year
- ✓ 3 Major Partnerships

Baxalta, KBI BIOPHARMA, Daiichi-Sankyo

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

Converging trends create a significant near-term global market opportunity for biosimilar development

- **Surge in 2012 – 2020 patent expirations**
- **Healthcare reform / regulatory enablement**
- **Better analytic tools enable comparability**
- **Payer need for biologics cost control**

Source: EvaluatePharma: 29 originator products with > $1 Bn in global sales losing patent exclusivity in at least one major market through 2020 had ~$106 billion in 2015 global sales

Copyright ©2016 All Rights Reserved.

The three key biosimilar uncertainty issues continue to decrease over time



"We share a joint commitment with companies like Coherus to create a vibrant biosimilars market place"
– Steve Miller, SVP & Chief Medical Officer, Express Scripts

Zarzio® is a registered trademark of Novartis AG
(1) Trend lines illustrative in nature (2) Anticipated

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

2016 kicked off with positive data across programs

Jan 2016
Positive Data
CHS-0214
Phase 3 RA Study

COHERUS AND BAXALTA ANNOUNCE CHS-0214 (ETANERCEPT BIOSIMILAR) MET PRIMARY EFFICACY ENDPOINT IN PHASE 3 RA STUDY

Feb 2016
Positive Data
CHS-1701
Reg.-Enabling Immuno. Study

COHERUS ANNOUNCES CHS-1701 (PEGFILGRASTIM BIOSIMILAR) MET BOTH PRIMARY ENDPOINTS IN REGISTRATION-ENABLING IMMUNOGENICITY STUDY

Mar 2016
Completed Enrollment
CHS-1420
Phase 3 Psoriasis Study

COMPLETED ENROLLMENT OF THE PHASE 3 PSORIASIS STUDY FOR CHS-1420 (ADALIMUMAB BIOSIMILAR)

Copyright ©2016 All Rights Reserved.

Coherus has strengthened its balance sheet

$100M Private Placement

KKR

HEALTHCARE ROYALTY PARTNERS

- Executed in Feb 2015
- Conversion premium: 60%, >2X that of certain other recent public deals
- Top-tier investors with strong track record and long-term investment horizon

+

$30M Milestone Payment

Baxalta

- Received in May 2016
- Milestone payment for completing all visits in the two Phase 3 trials for CHS-0214 (etanercept biosimilar)

- This financing will support three value inflection points
  - BLA for CHS-1701
  - MAA for CHS-0214
  - BLA for CHS-1420
- May also contribute through first approval

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

Key catalysts are on the near-term horizon across multiple programs



Unless otherwise noted, catalysts placed within 3 month achievement windows; (1) Expect to complete study late in the first half of this year & move forward with BLA filing directly thereafter

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

CHS-1701 pegfilgrastim biosimilar, provides near-term commercial opportunity

Pegfilgrastim profile is attractive

Commercial / Financial	✓ Large revenue opportunity ✓ Relatively modest competition ✓ Reasonably sized commercial footprint
Scientific / Clinical	✓ Strong CHRS scientific knowledge base ✓ Executable, reasonably sized studies ✓ Known mechanism of action
Legal	✓ Patent expirations appear clear ✓ Line extension strategy expiration ✓ Relatively well controlled "moderate"
Molecular / CMC	✓ Complex but well defined ✓ Limited heterogeneity ✓ Existing formulation stable, available

Large revenue opportunity

Neulasta WW annual revenues

US$ billion



Modest competition

Late-stage biosimilar pipeline for U.S. registration

Coherus BIOSCIENCES — SANDOZ — APOTEX ADVANCING GENERICS

BLA-enabling clinical → Filed

Source: EvaluatePharma, First Word

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

Agenda

- Introduction and Company Summary
- **Addressing the Regulatory Hurdles**
- Navigating the Legal Landscape
- Maximizing the Commercial Opportunity

Copyright ©2016 All Rights Reserved.

Demonstrating biosimilarity: totality of the data
Platform: navigating the pathway to approval

Cutting Edge Analytics

Process Science and Molecular Tuning

Clinical and Regulatory

Intellectual Property



Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

Sophisticated analytics define originator biologics and molecular heterogeneity production variability

Cutting Edge Analytics

Process Science and Molecular Tuning

Clinical and Regulatory

Intellectual Property





Biosimilar to What?



Internal Capability is Essential

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

Process science and cell biology
Molecular tuning is validated in non-clinical models



Intracellular metabolism directly impacts glycosylation and biologic actively at various scales

Copyright ©2016 All Rights Reserved.

Coherus signed strategic manufacturing agreement with KBI Biopharma for commercial supply of CHS-1701

Key partnership terms	
Term	3 Years with options to extend
COGS	~5% of Sales Price
Capacity commitment	~$900 M of product value by January 2018

KBI Biopharma	
Ownership	• JSR Corporation, large Japanese conglomerate
Facilities	• Durham, NC – 2,000L cell culture • Boulder, CO – 1,500L microbial
Capabilities(1)	• GMP Manufacturing, CMC submissions • Process characterization, validation, development • Antibodies, proteins, vaccines, peptides, oligonucleotides

(1) Not exhaustive

Copyright ©2016 All Rights Reserved.

Clinical and global regulatory
Clarify requirements, mitigate regulatory risk



Copyright ©2016 All Rights Reserved.

Agenda

- Introduction and Company Summary
- Addressing the Regulatory Hurdles
- **Navigating the Legal Landscape**
- Maximizing the Commercial Opportunity

Copyright ©2016 All Rights Reserved.

Scientific expertise focused on intellectual property

Scientific Advisory Board			
Name	**Role**	**Expertise**	**Prior Experience**
Bryan Lawlis, Ph.D.	Chairman	Process Sciences Biochemistry	Genentech, ARADIGM, COVANCE, Itero
Andy Jones, Ph.D.	Member	Protein Chemistry Glycobiology	Genentech A Member of the Roche Group
Bill Bennett, Ph.D.	Member	Protein Chemistry Regulatory	Genentech A Member of the Roche Group, COR, SENSUS
John Carpenter, Ph.D.	Member	Protein Formulation, Aggregation	University of Colorado Denver
James Miller, Ph.D.	Member	Protein Chemistry	AMGEN, REGENERON science to medicine™
Carl Ware, Ph.D.	Member	Inflammatory Disease	Sanford Burnham Medical Research Institute

Copyright ©2016 All Rights Reserved.

Scientific expertise is essential to intellectual property risk mitigation

Patent landscape assessment	Scientific Advisory Board	Innovation and IP creation
• Comp of matter • Indications • Formulation • Process • Dosing	• Reference experts • Industry knowledge • Technical assessment • Feasible alternatives	• Stable formulations • Cost effective processes • Protein structure / characterization • Global filings

Patent filing status	• **17 pending formulation US patents**(1), covering multiple formulation embodiments for our anti-TNF and pipeline products • **5 pending process patents**(1), covering production enhancements for our anti-TNF products

(1) In various stages of global nationalization

Copyright ©2016 All Rights Reserved.

Coherus – Patent Issuances in May 2016: Adalimumab formulations excluding polyol / surfactant

U.S. Patent 9,340,611	U.S. Patent 9,340,612	U.S. Patent 9,346,880
• Adalimumab, histidine buffer, amino acid stabilizer • Requires exclusion of polyol	• Adalimumab, buffer, stabilizer • Requires exclusion of polyol and surfactant	• Adalimumab, buffer, stabilizer • Requires exclusion of surfactant

Coherus patents may afford significant commercial advantage in light of AbbVie formulation patents that require these two excipients

Copyright ©2016 All Rights Reserved.

Adalimumab IP overview – Pathway to market requires IP navigation

Primary IP considerations to market for an adalimumab biosimilar(1)



(1) Not an exhaustive list of patents relating to adalimumab

Copyright ©2016 All Rights Reserved.

IPR timelines: Final decision on both '135 and '166 IPRs expected within 18 months, before planned FDA approval

Timeline of Coherus' IPRs filed on AbbVie Humira dosing and formulation patents



- Approx. 70% of instituted IPRs result in claim invalidation or settlement(3)
- Federal Circuit has rarely reversed USPTO final decisions

(1) Must occur within six months of filing
(2) Must occur within 12 months of institution
(3) USPTO - Protecting Biopharmaceutical Innovation—Litigation and Patent Office Procedures - Janet Gongola, Senior Advisor

Copyright ©2016 All Rights Reserved.

Coherus – '135 IPR
Rheumatoid arthritis 40 mg dosing patent IPR arguments



Copyright ©2016 All Rights Reserved.

Coherus – '166 IPR
Humira buffered formulation IPR arguments



Copyright ©2016 All Rights Reserved.

Agenda

- Introduction and Company Summary
- Addressing the Regulatory Hurdles
- Navigating the Legal Landscape
- **Maximizing the Commercial Opportunity**

Copyright ©2016 All Rights Reserved.

Coherus applies rigorous selection criteria to candidate molecules



Source: EvaluatePharma

Assessment
- Market Opportunity
- Patents & IP Analysis
- Technical Analysis

Development to Phase 1
- Molecule and Analytics
- Cell line and Manufacturing
- Clinical and Nonclinical

Phase 3
- Harmonization
- Global Sites
- Co-therapies

Commercial
- Payers, Providers, Patients
- Partners
- Promotion
- Legal Defense

- All technical and commercial factors must be holistically evaluated at key decision points
- Patent expiry and large existing markets are insufficient rationale for product selection

Copyright ©2016 All Rights Reserved.

Therapeutic area franchises link Coherus capabilities with customer needs

Create bundled product areas focused therapeutically



Platform enables development of biosimilar candidates in various therapeutic verticals

Product pipeline to leverage commercialization infrastructure

Copyright ©2016 All Rights Reserved.

Market differences drive tailored commercial responses in the two major markets

Oncology (CHS-1701)	Inflammation (Anti-TNFs)
Market Dynamics	
• Episodic, non-chronic care • Concentrated sites, clinic and hospital • GPO and provider driven adoption • Lower competitive intensity	• Multi-indication, chronic care • Larger, multiple specialist prescriber base • Payer driven adoption, PBM intermediary • Higher competitive intensity
Commercial Response	
• Specialty sales force < 50 • GPO and provider contracting • Education and conversion dynamics executable	• Specialty sales force > 150, Payer contracting • Competitive "patient friendly" formats / programs • Strong sales pull-through driving rapid conversion

Copyright ©2016 All Rights Reserved.

Potential platform throughput enables therapeutic franchise focus to maximize market value

Wave 1
Wave 2
Potential



(1) BLA enabling

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

Program development timing and milestones

CHS-1701 (pegfilgrastim biosimilar)		CHS-0214 (etanercept biosimilar)		CHS-1420 (adalimumab biosimilar)		Wave 2 assets	
Q2 '15	• PK/PD & immunogenicity studies initiated	Q2 '15	• Phase 3 PsO & RA studies enrolled	Q3 '15	• PsO study initiated	H1 '16	• Bevacizumab & Ranibizumab announced
Q1 '16	• Positive immunogenicity data	Q4 '15 – Q1 '16	• Positive Ph 3 PsO data • Positive Ph 3 RA data	Mid '16	• Phase 3 readouts	H2 '16	• Pipeline addition
Q2 '16	• PK/PD readout(1) • BLA filing directly thereafter(1)	H2 '16	• MAA filing	H2 '16	• BLA filing	H1 '17	• Pipeline addition

Unless otherwise noted, catalysts placed within 3 month achievement windows; (1) Expect to complete study late in the first half of this year & move forward with BLA filing directly thereafter

Copyright ©2016 All Rights Reserved.

Coherus BIOSCIENCES

Coherus BioSciences

May 2016

Copyright ©2016 All Rights Reserved.